Company insight
Advancing cartridge-based subcutaneous drug delivery
The Covid-19 pandemic has highlighted the importance and effectiveness of enabling patient self-administration in medication delivery. However, then comes the challenge of developing device technologies that support end user safety and usability – a need that SHL’s range of autoinjectors addresses.
T
he past five years have seen of defining moments in parenteral drug delivery. To start with, the five-year average for the FDA’s new molecular entities and biologics approvals currently sits at 51 drugs per year. A decade ago, it was 24. Of the many approvals pre and post-pandemic, there are a few standouts – a breakthrough therapy for atopic disorders was first approved in the US and EU in 2017. In 2020, the industry saw the regulatory approval of a 2ml autoinjector format of this biologic, a first in the self-injection space. Between these years, we have also seen notable advancements in formulation science facilitating better delivery of subcutaneous injections.
The composite of these scientific developments – aggravated by the pandemic – challenges the existing notion regarding the value of therapeutic self-administration and fortifies the merits of drug delivery devices like autoinjectors. For one, the reason behind the growth of autoinjectors is their ease of use. Autoinjectors are conventionally developed around the pre- filled syringe which, with their staked needles, can be designed into two-step or three-step self-injection devices that do not expose the user to the needle. In comparison, cartridge-based injectors traditionally require the user to manually attach the needle to the device before injection. This requires an extra step for the user and also poses a risk of contamination and needle stick injuries.
Potential for wider benefits The constant evolution of drug formulations across various disease areas opens a wider avenue for subcutaneous drug delivery. Recent developments in syringe-based systems, which have traditionally been limited to 1ml, have seen expanded dosing
Innovations in NIT have been developed to address challenges linked to cartridge-based autoinjectors.
volumes of up to 2.25ml. In comparison, cartridges can go up to 3ml, and at the same time we see the development of higher-volume cartridges holding 5ml or more. This expanded scope of container choices built upon self-injection technologies enables pharmaceutical companies to further explore cartridge- based autoinjectors for the next-generation of drug formulations under development. An innovative mechanism called Needle Isolation Technology (NIT) has been developed to address the challenges associated with cartridge-based injection systems. Based on a pre-installed needle hidden inside the device, the technology eliminates the need for users to manually attach the needle. With NIT, users simply untwist the cap to introduce the needle prior to injection, opening up the fluid path and allowing the injector to automatically prime. Because NIT makes it possible for the cartridge to behave like a traditional pre-
World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
filled syringe with a staked needle, it means that the device can be built into an integrated autoinjector with complete needle covering and shielding before and after injection. This cartridge-based technology also allows for increased delivered dose volume and accommodation of lyophilised or suspension formulations. The special formulations include drug treatments for type 2 diabetes. Recent treatments in the oncology area have been exploring the subcutaneous route through enzyme-assisted drug formulations, allowing potential for cartridge-based autoinjector combination product development. Finally, the technology supports complete control of cannula gauge and length to enable target injection time and depth.
Steps towards real change The first cartridge-based autoinjector built with NIT was approved by the FDA in 2017. The device, which is the second- generation device of the pharmaceutical company’s GLP-1 receptor agonist, offers its patients a more convenient injection experience. Since its commercialisation in 2018, the combination product has delivered millions of doses to patients worldwide. The autoinjector became the gold winner of the 2019 Medical Design Excellence Awards in the drug-delivery and combination products category. As we enter a post-pandemic healthcare landscape, SHL foresees that advancements in parenteral drug delivery will not waiver. With an evolving industry understanding of autoinjector devices, their usability, and the continued rise of novel drug formulations – cartridge-based subcutaneous drug delivery will continue to redefine the field of patient self-injection. ●
www.shl-medical.com 17
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49
